Evotec +1.4% at EUR4.45 after slightly better-than-expected '05 figures, says a trader. "However the progress of the development of the company's drugs are more important," he says. Notes it remains to be seen how analysts assess the company's statements on the matter. Sees next resistance at EUR4.58. (SMS/JUM)
Newratings